Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Punjab University College of Pharmacy, University of the Punjab, Lahore 54000, Pakistan.
Biomed Res Int. 2017;2017:4269875. doi: 10.1155/2017/4269875. Epub 2017 Oct 16.
Numerous medications are known to be associated with the development of lower urinary tract symptoms (LUTS). One such medication group is calcium channel blockers (CCB).
To critically examine the literature regarding the involvement of CCB in manifestation of LUTS in humans.
A systematic literature search was conducted on PubMed, SciELO, Scopus, and OpenGrey databases to find all potentially relevant research studies before August 2016.
Five studies met the inclusion criteria and were included in this review. Three out of five studies stated that CCB were involved in either precipitation or exacerbation of LUTS. As for the remaining two studies, one study found out that only the monotherapy of CCB was associated with increased prevalence of nocturia and voiding symptoms in young females, whereas the other study reported an inverse association of CCB with LUTS. The methodological quality of studies was considered high for four studies and low for one study.
Healthcare providers should make efforts for an earlier identification of the individuals at risk of LUTS prior to the commencement of CCB therapy. Moreover, patients should be counselled to notify their healthcare provider if they notice urinary symptoms after the initiation of CCB.
许多药物已知与下尿路症状（LUTS）的发展有关。钙通道阻滞剂（CCB）就是这样一种药物群体。
批判性地检查关于 CCB 在人类中表现出 LUTS 中的作用的文献。
在 2016 年 8 月之前，我们在 PubMed、SciELO、Scopus 和 OpenGrey 数据库上进行了系统的文献检索，以找到所有潜在的相关研究。
符合纳入标准的研究有 5 项，并被纳入本次综述。五项研究中的三项表明 CCB 参与了 LUTS 的发生或恶化。至于另外两项研究，一项研究发现，只有 CCB 的单一疗法与年轻女性夜尿症和排尿症状的发生率增加有关，而另一项研究报告了 CCB 与 LUTS 呈负相关。四项研究的方法学质量被认为较高，一项研究较低。
医疗保健提供者应努力在开始 CCB 治疗之前更早地识别出有 LUTS 风险的个体。此外，如果患者在开始 CCB 后注意到尿症状，应告知其医疗保健提供者。
